摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

17-(1-Hydroxy-ethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol

中文名称
——
中文别名
——
英文名称
17-(1-Hydroxy-ethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol
英文别名
20-alpha-Dihydropregenolone;17-(1-hydroxyethyl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
17-(1-Hydroxy-ethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol化学式
CAS
——
化学式
C21H34O2
mdl
——
分子量
318.5
InChiKey
QAAQQTDJEXMIMF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    23
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.9
  • 拓扑面积:
    40.5
  • 氢给体数:
    2
  • 氢受体数:
    2

文献信息

  • Conjugated Neuroactive Steroid Compositions And Methods Of Use
    申请人:Marx Christine
    公开号:US20130245253A1
    公开(公告)日:2013-09-19
    The present disclosure provides modified neuroactive steroids. The modified neuroactive steroids may comprise, consist of, or consist essentially of a therapeutic agent and/or a modifying moiety. The modified neuroactive steroid can have modified characteristics as compared to native neuroactive steroids that do not include a modifying moiety and/or therapeutic agent. The modified neuroactive steroid may be, for example, modified pregnenolone, pregnenolone metabolites, allopregnanolone, and/or allopregnanolone metabolites. The modified neuroactive steroids can be used to treat, prevent and/or ameliorating a phenotypic state of interest in a subject.
  • US7365218B2
    申请人:——
    公开号:US7365218B2
    公开(公告)日:2008-04-29
  • [EN] CONJUGATED NEUROACTIVE STEROID COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSITIONS DE STÉROÏDE NEUROACTIF CONJUGUÉ ET LEURS PROCÉDÉS D'UTILISATION
    申请人:UNIV DUKE
    公开号:WO2011120044A1
    公开(公告)日:2011-09-29
    The present disclosure provides modified neuroactive steroids. The modified neuroactive steroids may comprise, consist of, or consist essentially of a therapeutic agent and/or a modifying moiety. The modified neuroactive steroid can have modified characteristics as compared to native neuroactive steroids that do not include a modifying moiety and/or therapeutic agent. The modified neuroactive steroid may be, for example, modified pregnenolone, pregnenolone metabolites, allopregnanolone, and/or allopregnanolone metabolites. The modified neuroactive steroids can be used to treat, prevent and/or ameliorating a phenotypic state of interest in a subject.
查看更多